

□ **Cat. #ODN4084F-1**

ODN 4084-F-Class B Inhibitory TLR9 Antagonist, antigen grade

**Size: 200 ug**

CpG oligodeoxynucleotides (or CpG ODN) are short single-stranded synthetic DNA molecules that contain an unmethylated CG (Cytosine–guanine) di nucleotide in a specific base sequence (CpG motifs). The p refer to the phosphodiester backbone. These CpG motifs are not seen in eukaryotic DNA are considered pathogen-associated molecular patterns (PAMPs). The CpG PAMP is recognized by (TLR9). 3 types of, inhibitory ODNs have been identified.

Class B INH-ODNs are broadly reactive linear ODNs that potently block CpG-induced activation in all TLR9-expressing cells.

Class R INH-ODNs are capable of making significant secondary structures and are less active in resting B cells.

Class G. Class G INH-ODNs contain multiple G3 triplets (like telomeric repeats) or G4 tetrads and are capable of making large G-aggregates. They inhibit not only signaling through the TLR9, but also activation through other TLRs. They are directly pro apoptotic in tumor cells and can additionally block stimulation of other immune cells.

**ODN 4084-F** is a class B inhibitory ODNs. It contains an inhibitory DNA motif consisting of two nucleotide triplets, a proximal CCT and a more distal GGG, spaced from each other by four nucleotides. ODN 4084-F is the shortest active inhibitory ODN. ODN 4084-F is linear and a class B ('broadly-active') inhibitory ODN. ODN 4084-F is potent inhibitor of TLR9-induced B cells and macrophages

**Cat. #:ODN4084F-1 & ODN4084F-5**

<b>Sequence</b>	5'-cctggatgggaa-3' (15 mer)
<b>Purity</b>	≥95%
<b>Form and storage</b>	Powder. After reconstitution, Store at -20C up to 1 year
<b>Shipping</b>	Shipped at 4° C
<b>Endotoxin</b>	<0.002 EU/μg
<b>Solubility</b>	water, PBS or other buffers (up to 5 mg/ml)

**Notes:**

- 1) Bases in capital are phosphodiester and those in lower case are phosphorothioate. Palindromic sequences are underlined.
- 2) Negative control Contains GpC nucleotides instead of CpG.

**General references:** Krieg, A.M(1995). Nature, 374(6522):546-9. Ballaz ZK(2001) 167(9). Bauer, (2001). PNAS98(16):9237-42 3 P. S. Lenert, (2006) *Arthritis Research and Therapy*, (8), no. 1, article R203

**Related Items**

Catalog#	ProdDescription
ODN006-1	ODNBW006 Type B CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3' end
ODN1668-1	ODN 1668-Type B murine TLR9 Agonist-Antigen grade
ODN 1668-	Type B murine TLR9 Agonist (Negative Control), antigen grade
ODN1826-1	ODN 1826- Type B murine TLR9 Agonist-antigen grade
ODN2006-1	ODN 2006 -Type B-human TLR9 agonist-antigen grade
ODN2007-1	ODN 2007-Type B bovine/porcineTLR9 agonist-antigen grade
ODN2216-1	ODN 2216-Type A human TLR9 Agonist- antigen grade
ODN2395-5	ODN 2395-Type C human/murine TLR9 agonist-antigen grade
ODN4084F-1	ODN 4084-Type B Inhibitory TLR9 Antagonist- antigen grade
ODN4084F-5	ODN 4084-Type B Inhibitory TLR9 Antagonist- antigen grade
ODNTT-1NC	ODN TTAGGG-Class G Human-TLR 9 Antagonist, antigen grade
SIODN-1	Inhibitory iODN- class I/II hybrid, may also affect TLR7 and TLR8 signaling.

**ODN4084**

**140217P**